Is currently used as a comprehensive definition covering “brain disorders”, neurological diseases and mental disorders. While
schizophrenia, depression, panic disorder, drug addiction and insomnia are referred to as “mental disorders”, Epilepsy, Alzheimer,
Parkinson, Huntington’s disease (HD) and multiple sclerosis are considered as “neurological disorders”. Current therapies
of these very common diseases require continuous drug use and at the same time cause many different side effects. Therefore
preclinical and clinical investigations for new treatment approaches are on the rise. Especially the identification of the molecular
basis of these diseases is the focus of researches.
Examination of transient receptor potential (TRP) channels is at an early stage in the investigation of the molecular principle of
these diseases, but clear results regarding the efficacy of substances activating or inhibiting these channels have not been obtained.
Some diseases have been based on mutations of TRP channels. However, only a few TRP channelopathies, have been conclusively
identified so far . Investigation of TRP channels in psychiatric disorders will contribute to a better understanding of the etiology
of psychiatric disorders and the development of new pharmacological treatments.
Abbreviations: TRP: Transient Receptor Potential; GPCR: G Protein Coupled Receptor; TRPV1: TRP Vanilloid 1; CGRP: Calcitonin
Gene Related Peptide; CNS: Central Nervous System; SOC: Store Operated Calcium Channels; BDNF: Brain Derived Neurotrophic
Factor; Mwk: Moon Walker Mouse; BD-I: Bipolar Disorder Type I; ALS-G: Guamanian Amyotrophic Lateral Sclerosis